Literature DB >> 8426202

Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age.

J F Abrahamsen1, A Andersen, E Hannisdal, O Nome, A F Abrahamsen, S Kvaløy, H Høst.   

Abstract

PURPOSE: In the period 1968 through 1988, The Norwegian Radium Hospital (NRH) treated an unselected population of 1,152 patients with Hodgkin's disease (HD) that comprised more older patients (mean age, 43 years) than most other institutions. We considered it important to evaluate these patients for development of second cancers (SCs). PATIENTS AND METHODS: The Norwegian Cancer Registry identified previously untreated patients with HD treated at NRH who had developed a SC more than 1 year after diagnosis of HD. The relative risk ratio (RR) (observed/expected cases) and the cumulative risk were calculated.
RESULTS: Sixty-eight patients had developed a SC, including nine acute nonlymphocytic leukemias (ANLLs), eight non-Hodgkin's lymphomas (NHLs), and 51 solid tumors, including 11 lung cancers. The RR of SC and leukemia was 1.86 (95% confidence interval [CI], 1.4 to 2.4) and 24.3 (95% CI, 11.1 to 46.2), respectively. The RR of SC was highest in younger patients (< 41 years, RR = 3.8). No significant association between splenectomy and development of ANLL was found. The influence of treatment and follow-up time on the development of SC agrees with data from other large cancer institutions.
CONCLUSION: (1) The low RR of developing a SC in this study is probably due to the number of older patients included, who have a lower RR of developing a SC due to less aggressive treatment, shorter follow-up time, and higher incidence of cancer in the expected background population. (2) The low RR and cumulative risk of developing ANLL may be due to the limited use of extensive chemotherapy (CT) in our hospital in the earlier years.

Entities:  

Mesh:

Year:  1993        PMID: 8426202     DOI: 10.1200/JCO.1993.11.2.255

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  19 in total

1.  Intraductal tubulopapillary neoplasm of the pancreas as a radiation induced malignancy.

Authors:  Neel Bhuva; Harpreet Wasan; Duncan Spalding; Gordon Stamp; Mark Harrison
Journal:  BMJ Case Rep       Date:  2011-12-08

2.  [Secondary malignancies after successful primary treatment of malignant Hodgkin's lymphoma].

Authors:  P Borchmann; K Behringer; A Josting; J U Rueffer; R Schnell; V Diehl; A Engert; H M Kvasnicka; J Thiele
Journal:  Pathologe       Date:  2006-02       Impact factor: 1.011

3.  Radiation-induced breast cancer in women with Hodgkin's disease.

Authors:  Elena Aleksandrova; Iglika Mihaylova; Sonya Sergieva; Vesselina Parvanova; Doroteya Ivanova
Journal:  Rep Pract Oncol Radiother       Date:  2014-07-16

Review 4.  ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II.

Authors:  Sughosh Dhakal; Ranjana Advani; Leslie K Ballas; Bouthaina S Dabaja; Christopher R Flowers; Chul S Ha; Bradford S Hoppe; Nancy P Mendenhall; Monika L Metzger; John P Plastaras; Kenneth B Roberts; Ronald Shapiro; Sonali M Smith; Stephanie A Terezakis; Karen M Winkfield; Anas Younes; Louis S Constine
Journal:  Am J Clin Oncol       Date:  2016-12       Impact factor: 2.339

5.  Prolonged bone marrow failure with monosomy 7 after engraftment failure following bone marrow transplantation.

Authors:  R Kobayashi; H Arioka; M Yoshida; Y Cho; A Iguchi; M Kaneda; T Shikano
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

6.  [Second malignancies after the therapy of Hodgkin's disease: the Freiburg collective 1940 to 1991].

Authors:  J Slanina; F Heinemann; K Henne; G Moog; H Frommhold
Journal:  Strahlenther Onkol       Date:  1999-04       Impact factor: 3.621

Review 7.  Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk.

Authors:  J G Franklin; M D Paus; A Pluetschow; L Specht
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

Review 8.  Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.

Authors:  Jeremy Franklin; Dennis A Eichenauer; Ingrid Becker; Ina Monsef; Andreas Engert
Journal:  Cochrane Database Syst Rev       Date:  2017-09-13

9.  Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose.

Authors:  Louis S Constine; Nancy Tarbell; Melissa M Hudson; Cindy Schwartz; Susan G Fisher; Ann G Muhs; Swati K Basu; Larry E Kun; Andrea Ng; Peter Mauch; Ajay Sandhu; Eva Culakova; Gary Lyman; Nancy Mendenhall
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-09-01       Impact factor: 7.038

10.  [Hodgkin's disease and secondary colon cancer: report of a case].

Authors:  Lamia Boulaâmane; El Mehdi Tazi; Meryem Glaoui; Ghizlane Raiss; Issam Lalya; Saber Boutayeb; Hind M'rabti; Hassan Errihani
Journal:  Pan Afr Med J       Date:  2011-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.